22 research outputs found
The Incidence of AIDS-Defining Illnesses at a Current CD4 Count â„200 Cells/”L in the Post-Combination Antiretroviral Therapy Era
The incidence of AIDS was higher in patients with a current CD4 count of 500-749 cells/”L compared to 750-999 cells/”L, but did not decrease further at higher CD4 levels. Results were similar in those virologically suppressed on combination antiretroviral therapy, suggesting immune reconstitution is incomplete until CD4 >750/”
GA4GH: International policies and standards for data sharing across genomic research and healthcare.
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits
Water Oxidation Catalysis with Ligand Substituted Ru-bpp-type Complexes
A series of symmetric and non-symmetric dinuclear Ru complexes of general formula {[Ru(R2-trpy)(H2O)][Ru(R3-trpy)(H2O)](μ-R1-bpp)}3+ where trpy is 2,2′:6′,2′′-terpyridine, bpp− is 3,5-bis(2-pyridyl)-pyrazolate and R1, R2 and R3 are electron donating (ED) and electron withdrawing (EW) groups such as Me, MeO, NH2 and NO2 have been prepared using microwave assisted techniques. These complexes have been thoroughly characterized by means of analytical (elemental analysis), spectroscopic (UV-vis, NMR) and electrochemical (CV, SQWV, CPE) techniques. The single crystal X-ray structures for one acetate- and one chloro-bridged precursor have also been solved. Kinetic analysis monitored by UV-vis spectroscopy reveals the electronic effects exerted by the ED and EW groups on the substitution kinetics and stoichiometric water oxidation reaction. The catalytic water oxidation activity is evaluated by means of chemically (CeIV), electrochemically, and photochemically induced processes. It is found that, in general, ED groups do not strongly affect the catalytic rates whereas EW groups drastically reduce catalytic rates. Finally, DFT calculations provide a general and experimentally consistent view of the different water oxidation pathways that can operate in the water oxidation reactions catalyzed by these complexes.</p
Moderate-vigorous physical activity across body mass index in females: moderating effect of endocannabinoids and temperament
BACKGROUND:
Endocannabinoids and temperament traits have been linked to both physical activity and body mass index (BMI) however no study has explored how these factors interact in females. The aims of this cross-sectional study were to 1) examine differences among distinct BMI groups on daytime physical activity and time spent in moderate-vigorous physical activity (MVPA), temperament traits and plasma endocannabinoid concentrations; and 2) explore the association and interaction between MVPA, temperament, endocannabinoids and BMI.
METHODS:
Physical activity was measured with the wrist-worn accelerometer Actiwatch AW7, in a sample of 189 female participants (43 morbid obese, 30 obese, and 116 healthy-weight controls). The Temperament and Character Inventory-Revised questionnaire was used to assess personality traits. BMI was calculated by bioelectrical impedance analysis via the TANITA digital scale. Blood analyses were conducted to measure levels of endocannabinoids and endocannabinoid-related compounds. Path-analysis was performed to examine the association between predictive variables and MVPA.
RESULTS:
Obese groups showed lower MVPA and dysfunctional temperament traits compared to healthy-weight controls. Plasma concentrations of 2-arachidonoylglyceryl (2-AG) were greater in obese groups. Path-analysis identified a direct effect between greater MVPA and low BMI (bâ=â-0.13, pâ=â.039) and high MVPA levels were associated with elevated anandamide (AEA) levels (bâ=â0.16, pâ=â.049) and N-oleylethanolamide (OEA) levels (bâ=â0.22, pâ=â.004), as well as high Novelty seeking (bâ=â0.18, p<.001) and low Harm avoidance (bâ=â-0.16, p<.001).
CONCLUSIONS:
Obese individuals showed a distinct temperament profile and circulating endocannabinoids compared to controls. Temperament and endocannabinoids may act as moderators of the low MVPA in obesity
Associations of the MCM6-rs3754686 proxy for milk intake in Mediterranean and American populations with cardiovascular biomarkers, disease and mortality: Mendelian randomization
Controversy persists on the association between dairy products, especially milk, and cardiovascular
diseases (CVD). Genetic proxies may improve dairy intake estimations, and clarify diet-disease
relationships through Mendelian randomization. We meta-analytically (n †20,089) evaluated
associations between a lactase persistence (LP) SNP, the minichromosome maintenance complex
component 6 (MCM6)-rs3754686C>T (nonpersistence>persistence), dairy intake, and CVD biomarkers
in American (Hispanics, African-American and Whites) and Mediterranean populations. Moreover,
we analyzed longitudinal associations with milk, CVD and mortality in PREDIMED), a randomized
Mediterranean diet (MedDiet) intervention trial (n = 7185). The MCM6-rs3754686/MCM6-rs309180
(as proxy), LP-allele (T) was strongly associated with higher milk intake, but inconsistently associated
with glucose and lipids, and not associated with CVD or total mortality in the whole population.
Heterogeneity analyses suggested some sex-specific associations. The T-allele was associated with higher CVD and mortality risk in women but not in men (P-sex interaction:0.005 and 0.032,
respectively), mainly in the MedDiet group. However, milk intake was not associated with CVD
biomarkers, CVD or mortality either generally or in sub-groups. Although MCM6-rs3754686 is a
good milk intake proxy in these populations, attributing its associations with CVD and mortality in
Mediterranean women to milk is unwarranted, as other factors limiting the assumption of causality in
Mendelian randomization may exist
Recommended from our members
Registered access: authorizing data access
The Global Alliance for Genomics and Health (GA4GH) proposes a data access policy model-"registered access"-to increase and improve access to data requiring an agreement to basic terms and conditions, such as the use of DNA sequence and health data in research. A registered access policy would enable a range of categories of users to gain access, starting with researchers and clinical care professionals. It would also facilitate general use and reuse of data but within the bounds of consent restrictions and other ethical obligations. In piloting registered access with the Scientific Demonstration data sharing projects of GA4GH, we provide additional ethics, policy and technical guidance to facilitate the implementation of this access model in an international setting
Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).
Remote ischemic conditioning (RIC) and the GLP-1 analog exenatide activate different cardioprotective pathways and may have additive effects on infarct size (IS). Here, we aimed to assess the efficacy of RIC as compared with sham procedure, and of exenatide, as compared with placebo, and the interaction between both, to reduce IS in humans. We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial. Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo. The primary outcome was IS measured by late gadolinium enhancement in cardiac magnetic resonance performed 3-7 days after PPCI. The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume. A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. IS was similar between groups for the RIC (24â±â11.8% in the RIC group vs 23.7â±â10.9% in the sham group, Pâ=â0.827) and the exenatide hypotheses (25.1â±â11.5% in the exenatide group vs 22.5â±â10.9% in the placebo group, Pâ=â0.092). There were no effects with either RIC or exenatide on the secondary outcomes. Unexpected adverse events or side effects of RIC and exenatide were not observed. In conclusion, neither RIC nor exenatide, or its combination, were able to reduce IS in STEMI patients when administered as an adjunct to PPCI.The trial was sponsored with a Grant from Instituto de Salud Carlos III (PIE 13/00027) and a Grant from Generalitat de Catalunya (PERIS SLT/2381/2016). The sponsors have not been involved in the design, conduct, collection, analysis, interpretation of the data, nor in the preparation, review or approval of the manuscriptS
Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals
Decisions about when to start or switch a therapy often depend on the
frequency with which individuals are monitored or tested. For example,
the optimal time to switch antiretroviral therapy depends on the
frequency with which HIV-positive individuals have HIV RNA measured.
This paper describes an approach to use observational data for the
comparison of joint monitoring and treatment strategies and applies the
method to a clinically relevant question in HIV research: when can
monitoring frequency be decreased and when should individuals switch
from a first-line treatment regimen to a new regimen? We outline the
target trial that would compare the dynamic strategies of interest and
then describe how to emulate it using data from HIV-positive individuals
included in the HIV-CAUSAL Collaboration and the Centers for AIDS
Research Network of Integrated Clinical Systems. When, as in our
example, few individuals follow the dynamic strategies of interest over
long periods of follow-up, we describe how to leverage an additional
assumption: no direct effect of monitoring on the outcome of interest.
We compare our results with and without the âno direct effectâ
assumption. We found little differences on survival and AIDS-free
survival between strategies where monitoring frequency was decreased at
a CD4 threshold of 350 cells/mu l compared with 500 cells/mu l and where
treatment was switched at an HIV-RNA threshold of 1000 copies/ml
compared with 200 copies/ml. The âno direct effectâ assumption
resulted in efficiency improvements for the risk difference estimates
ranging from an 7- to 53-fold increase in the effective sample size